National Institute of Allergy and Infectious Diseases (NIAID): Respiratory Syncytial Virus Infections trials
The registry lists 21 Respiratory Syncytial Virus Infections studies with National Institute of Allergy and Infectious Diseases (NIAID) as lead sponsor. 0 are open to participants now and 7 have results posted.
Phase 1 18Phase 3 1Phase 4 2(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- Evaluating the Infectivity, Safety and Immunogenicity of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine, LID/ΔM2-2/1030s, in RSV-Seronegative Infants and Children 6 to 24 Months of AgeCompletedNCT04520659Phase 1Results posted
- Evaluating the Infectivity, Safety and Immunogenicity of Respiratory Syncytial Virus Vaccines, RSV 6120/∆NS1 and RSV 6120/F1/G2/∆NS1, in RSV-Seropositive Children and RSV-Seronegative Infants and ChildrenCompletedNCT03596801Phase 1Results posted
- Evaluating the Infectivity, Safety, and Immunogenicity of a Respiratory Syncytial Virus Vaccine (RSV 6120/∆NS2/1030s) in RSV-Seropositive Children and RSV-Seronegative Infants and ChildrenCompletedNCT03387137Phase 1Results posted
- Evaluating the Infectivity, Safety, and Immunogenicity of Recombinant Live-Attenuated RSV Vaccines RSV ΔNS2/Δ1313/I1314L or RSV 276 in RSV-Seronegative Infants 6 to 24 Months of AgeCompletedNCT03227029Phase 1Results posted
- Evaluating the Infectivity, Safety, and Immunogenicity of a Single Dose of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine (D46/NS2/N/ΔM2-2-HindIII) in RSV-Seronegative Infants 6 to 24 Months of AgeCompletedNCT03102034Phase 1Results posted
- Evaluating the Infectivity, Safety and Immunogenicity of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine (RSV LID cp ΔM2-2) in RSV-Seronegative Infants 6 to 24 Months of AgeTerminatedNCT02890381Phase 1Results posted
- Evaluating the Infectivity, Safety and Immunogenicity of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine in RSV-Seronegative Infants 6 to 24 Months of AgeCompletedNCT02794870Phase 1Results posted
- The Immunology and Safety of Maternal RSV Vaccination (ABRYSVO), Infant Nirsevimab (BEYFORTUS) Immunization, or Both ProductsCompletedNCT06551506Phase 4
- Inpatient Challenge Study of rRSV A/Maryland/001/11, a Human Respiratory Syncytial Virus Challenge Strain, Administered to Healthy Adult VolunteersCompletedNCT03624790Phase 1
- A Safety and Immunogenicity Study of Intranasal Sendai Virus Vectored Respiratory Syncytial Virus (SeVRSV) Vaccine in Healthy AdultsCompletedNCT03473002Phase 1
- Evaluating the Infectivity, Safety, and Immunogenicity of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine in RSV-Seronegative Infants and Children 6 to 24 Months of AgeCompletedNCT02952339Phase 1
- Infectivity, Safety and Immunogenicity of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine (RSV LID cp ΔM2-2) in RSV-Seronegative Infants and Children 6 to 24 Months of AgeTerminatedNCT02948127Phase 1
- Safety and Immunogenicity of the RSV D46cpΔM2-2 Vaccine in RSV-Seropositive Children and RSV-Seronegative Infants and ChildrenCompletedNCT02601612Phase 1
- Safety and Immune Response to a Live-Attenuated Respiratory Syncytial Virus (RSV) Vaccine in RSV-Seronegative Infants and ChildrenCompletedNCT02237209Phase 1
- Safety and Immune Response to a Live-Attenuated Respiratory Syncytial Virus (RSV) Vaccine in RSV-Seronegative Infants and ChildrenCompletedNCT02040831Phase 1
- Evaluating the Safety and Immune Response to a Single Dose of a Respiratory Syncytial Virus (RSV) Vaccine in RSV-Seronegative Infants and ChildrenCompletedNCT01968083Phase 1
- Evaluating the Safety and Immune Response to a Single Dose of a Respiratory Syncytial Virus (RSV) Vaccine in Infants and ChildrenCompletedNCT01893554Phase 1
- Evaluating the Safety and Immune Response to a Single Dose of a Respiratory Syncytial Virus (RSV) Vaccine in RSV-Seronegative Infants and ChildrenCompletedNCT01852266Phase 1
- Evaluating the Safety and Immune Response to a Respiratory Syncytial Virus (RSV) Vaccine in Adults, RSV-Seropositive Children, and RSV-Seronegative Infants and ChildrenCompletedNCT01459198Phase 1
- Ribavirin to Prevent RSV Pneumonia in Bone Marrow Transplant PatientsTerminatedNCT00031473Phase 3
- Prevention of RSV Infections in Bone Marrow Transplant RecipientsCompletedNCT00001903Phase 4